Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing
Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly i...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2024-04-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231210274 |
_version_ | 1797214438759071744 |
---|---|
author | Lele Song Yuan Gong Erpeng Wang Jianchun Huang Yuemin Li |
author_facet | Lele Song Yuan Gong Erpeng Wang Jianchun Huang Yuemin Li |
author_sort | Lele Song |
collection | DOAJ |
description | Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors. The specific composition of cell subtypes may facilitate or hamper the response to immunotherapy and influence patient prognosis. Various markers have been found to stratify the patient prognosis or predict the therapeutic outcome. In this article, we systematically reviewed the recent advancement of TIME studies in lung adenocarcinoma (LUAD) using single-cell RNA sequencing (scRNA-seq) techniques, with specific focuses on the roles of TIME in LUAD development, TIME heterogeneity, indications of TIME in patient prognosis and therapeutic response during immunotherapy and drug resistance. The main findings in TIME heterogeneity and relevant markers or models for prognosis stratification and response prediction have been summarized. We hope that this review provides an overview of TIME status in LUAD and an inspiration for future development of strategies and biomarkers in LUAD treatment. |
first_indexed | 2024-04-24T11:14:11Z |
format | Article |
id | doaj.art-a42f93ab98394008a21967391f9f3588 |
institution | Directory Open Access Journal |
issn | 1758-8359 |
language | English |
last_indexed | 2024-04-24T11:14:11Z |
publishDate | 2024-04-01 |
publisher | SAGE Publishing |
record_format | Article |
series | Therapeutic Advances in Medical Oncology |
spelling | doaj.art-a42f93ab98394008a21967391f9f35882024-04-11T10:04:01ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-04-011610.1177/17588359231210274Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencingLele SongYuan GongErpeng WangJianchun HuangYuemin LiTumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors. The specific composition of cell subtypes may facilitate or hamper the response to immunotherapy and influence patient prognosis. Various markers have been found to stratify the patient prognosis or predict the therapeutic outcome. In this article, we systematically reviewed the recent advancement of TIME studies in lung adenocarcinoma (LUAD) using single-cell RNA sequencing (scRNA-seq) techniques, with specific focuses on the roles of TIME in LUAD development, TIME heterogeneity, indications of TIME in patient prognosis and therapeutic response during immunotherapy and drug resistance. The main findings in TIME heterogeneity and relevant markers or models for prognosis stratification and response prediction have been summarized. We hope that this review provides an overview of TIME status in LUAD and an inspiration for future development of strategies and biomarkers in LUAD treatment.https://doi.org/10.1177/17588359231210274 |
spellingShingle | Lele Song Yuan Gong Erpeng Wang Jianchun Huang Yuemin Li Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing Therapeutic Advances in Medical Oncology |
title | Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing |
title_full | Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing |
title_fullStr | Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing |
title_full_unstemmed | Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing |
title_short | Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing |
title_sort | unraveling the tumor immune microenvironment of lung adenocarcinoma using single cell rna sequencing |
url | https://doi.org/10.1177/17588359231210274 |
work_keys_str_mv | AT lelesong unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing AT yuangong unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing AT erpengwang unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing AT jianchunhuang unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing AT yueminli unravelingthetumorimmunemicroenvironmentoflungadenocarcinomausingsinglecellrnasequencing |